… in chronic myeloid leukemia (CML). TKI therapy has since revolutionized the treatment of CML
… Prior to the 2001 approval of imatinib, interferon-α (IFN-α)-based treatment regimens were …

… Chronic myeloid leukemia (CML) is a neoplastic disease … important roles in prognosis and
treatment strategies. Philadelphia (Ph… CML: chronic myeloid leukemia; INF-α: interferon-α; TKI: …

… Introduction: Since the introduction of tyrosine kinase inhibitors (TKIs) therapy, chronic myeloid
leukemia (CML), has moved from a fatal illness to a manageable disease with a possible …

… Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive
options for patients with ET and PV at high risk for vascular complications. Myeloproliferative …

… therapy. Results appear independent of both dose reduction and potential pretreatment with
interferon-α… of chronic myeloid leukemia (CML). Currently, the life expectancy of patients in …

… Current treatment options for these diseases include supportive care, cytoreductive therapies,
interferon-α, and intensive chemotherapies [17,18]. The main aims of these therapies are …

… [21] Likewise, pegylated interferon-α in combination with imatinib leads to a significant
increase in the rate of major molecular response (MMR) at one year compared to imatinib alone, …

… The binding of IFNα to the interferon-α/β receptor (IFNAR) leads to the phosphorylation of
the signal transducer and activator of transcription 1 (STAT1) and up-regulation of a panel of …

… Interferon α (IFNα) has demonstrated some efficacy in inducing molecular remission in … and
may transform into secondary acute myeloid leukemia. MPN occurrence is mostly associated …

… traps, interferon-α, and allografting in the current treatment algorithm for … treatment options,
chronic myeloproliferative malignancies, with the exception of chronic myeloid leukemia (CML…